Pharmaceutical Sales Certification (PSC) & CNPR
Exam Practice Questions
Complete Study Guide with Verified Answers &
Detailed Rationales
2026/2027 Edition | National Association of Pharmaceutical Sales
Representatives (NAPSRx)
1. A pharmaceutical sales representative is preparing a presentation
for a hospital formulary committee on a new anticoagulant. The drug
shows a 30% relative risk reduction in stroke compared to warfarin,
but the absolute risk reduction is only 1.2%. The number needed to
treat (NNT) is approximately 83. The representative wants to highlight
the drug's efficacy. Which of the following statements is most accurate
and compliant with FDA guidelines on fair balance in promotional
materials?
• A) The drug reduces stroke risk by 30%, making it significantly more
effective than warfarin.
• B) The drug prevents one stroke for every 83 patients treated,
compared to warfarin.
• C) The absolute risk reduction of 1.2% indicates a modest benefit over
warfarin.
• D) The relative risk reduction of 30% is the most clinically
meaningful measure for patients.
Rationale: Option B presents the NNT, which is a balanced and clinically
relevant measure. Option A overemphasizes relative risk without context,
which can be misleading. Option C is accurate but may understate benefit in
,a promotional context. Option D disregards fair balance by favoring relative
risk. FDA guidance requires presenting both absolute and relative risk or
using NNT to avoid misleading claims .
2. A pharmaceutical company is launching a new biologic for psoriasis.
The drug is a monoclonal antibody that inhibits IL-17. During a sales
call, a dermatologist asks about the potential for immunogenicity and
its impact on efficacy and safety. Which of the following responses is
most accurate based on current scientific understanding and
regulatory labeling requirements?
• A) Immunogenicity is rare with fully human monoclonal antibodies,
and any neutralizing antibodies do not affect efficacy significantly.
• B) The incidence of anti-drug antibodies is low, but if present,
they may reduce efficacy and increase infusion reactions; the
label includes this information.
• C) Immunogenicity is not a concern for this class of biologics because
IL-17 inhibitors are small molecules.
• D) The drug is designed to avoid immunogenicity, and no antibody
testing is required during clinical trials.
Rationale: Option B accurately states that immunogenicity can occur and
may impact efficacy and safety, and that labeling must disclose this. Option A
is incorrect because even fully human antibodies can elicit immune
responses. Option C is false; IL-17 inhibitors are biologics, not small
molecules. Option D is incorrect; clinical trials routinely monitor for anti-drug
antibodies .
3. A sales representative is analyzing a pharmacy benefit manager's
(PBM) formulary tier placement for a new oral diabetes medication.
,The PBM has placed the drug on Tier 3 (preferred brand) with a prior
authorization requirement. The representative wants to increase
utilization. Which of the following strategies is most likely to be
effective and compliant with anti-kickback statutes?
• A) Offer the PBM a volume-based rebate tied to market share
growth, structured as a discount on list price.
• B) Provide free drug samples to the PBM's network physicians to
encourage prescribing.
• C) Sponsor a continuing medical education (CME) program on
diabetes management with an unrestricted educational grant.
• D) Pay a copay assistance program for patients to reduce out-of-
pocket costs, without income verification.
Rationale: Volume-based rebates structured as discounts are generally
permissible under the Anti-Kickback Statute if properly disclosed and not tied
to specific patients. Option B may implicate the federal Anti-Kickback Statute
as free samples can induce prescribing. Option C is permissible but indirect
and may not directly address tier placement. Option D could violate the Anti-
Kickback Statute if it is used to induce the use of a particular drug without
regard to medical necessity .
4. In a sales training session, a manager discusses the importance of
understanding the 'buying center' in a large academic medical center.
Which of the following best describes the composition of the buying
center for a new oncology drug, considering the roles of various
stakeholders?
• A) The pharmacy and therapeutics (P&T) committee alone makes the
formulary decision; prescribers and patients have no formal role.
• B) The buying center includes the P&T committee, key prescribers
(oncologists), pharmacy directors, and financial administrators;
each has distinct influence on adoption.
, • C) Only the hospital CEO and chief financial officer decide on drug
adoption based on budget impact.
• D) The buying center is limited to the medical director and the
pharmacy director; other stakeholders are consulted but not decision-
makers.
Rationale: In large institutions, the buying center is multi-disciplinary,
including P&T committee, prescribers, pharmacy, and finance. Option A is too
narrow; prescribers and patients influence decisions indirectly. Option C is
incorrect because clinical input is crucial. Option D underestimates the role of
the P&T committee and other stakeholders .
5. A sales representative is presenting a new antihypertensive drug
that combines an ACE inhibitor and a thiazide diuretic. The
representative claims that the combination has a synergistic effect on
blood pressure reduction. Which of the following physiological
mechanisms best explains the synergy between these two classes?
• A) ACE inhibitors increase renin release, while thiazides inhibit
aldosterone secretion, leading to additive natriuresis.
• B) Thiazides cause volume depletion, which activates the renin-
angiotensin-aldosterone system; ACE inhibitors block this
compensatory response.
• C) ACE inhibitors directly dilate renal afferent arterioles, while
thiazides constrict efferent arterioles, increasing glomerular filtration
rate.
• D) Both drugs inhibit the same enzyme, leading to a cumulative effect
on angiotensin II levels.
Rationale: Thiazide diuretics reduce blood pressure by depleting sodium and
water, which activates the renin-angiotensin-aldosterone system (RAAS). ACE
inhibitors block this compensatory response, resulting in a synergistic
antihypertensive effect .
Exam Practice Questions
Complete Study Guide with Verified Answers &
Detailed Rationales
2026/2027 Edition | National Association of Pharmaceutical Sales
Representatives (NAPSRx)
1. A pharmaceutical sales representative is preparing a presentation
for a hospital formulary committee on a new anticoagulant. The drug
shows a 30% relative risk reduction in stroke compared to warfarin,
but the absolute risk reduction is only 1.2%. The number needed to
treat (NNT) is approximately 83. The representative wants to highlight
the drug's efficacy. Which of the following statements is most accurate
and compliant with FDA guidelines on fair balance in promotional
materials?
• A) The drug reduces stroke risk by 30%, making it significantly more
effective than warfarin.
• B) The drug prevents one stroke for every 83 patients treated,
compared to warfarin.
• C) The absolute risk reduction of 1.2% indicates a modest benefit over
warfarin.
• D) The relative risk reduction of 30% is the most clinically
meaningful measure for patients.
Rationale: Option B presents the NNT, which is a balanced and clinically
relevant measure. Option A overemphasizes relative risk without context,
which can be misleading. Option C is accurate but may understate benefit in
,a promotional context. Option D disregards fair balance by favoring relative
risk. FDA guidance requires presenting both absolute and relative risk or
using NNT to avoid misleading claims .
2. A pharmaceutical company is launching a new biologic for psoriasis.
The drug is a monoclonal antibody that inhibits IL-17. During a sales
call, a dermatologist asks about the potential for immunogenicity and
its impact on efficacy and safety. Which of the following responses is
most accurate based on current scientific understanding and
regulatory labeling requirements?
• A) Immunogenicity is rare with fully human monoclonal antibodies,
and any neutralizing antibodies do not affect efficacy significantly.
• B) The incidence of anti-drug antibodies is low, but if present,
they may reduce efficacy and increase infusion reactions; the
label includes this information.
• C) Immunogenicity is not a concern for this class of biologics because
IL-17 inhibitors are small molecules.
• D) The drug is designed to avoid immunogenicity, and no antibody
testing is required during clinical trials.
Rationale: Option B accurately states that immunogenicity can occur and
may impact efficacy and safety, and that labeling must disclose this. Option A
is incorrect because even fully human antibodies can elicit immune
responses. Option C is false; IL-17 inhibitors are biologics, not small
molecules. Option D is incorrect; clinical trials routinely monitor for anti-drug
antibodies .
3. A sales representative is analyzing a pharmacy benefit manager's
(PBM) formulary tier placement for a new oral diabetes medication.
,The PBM has placed the drug on Tier 3 (preferred brand) with a prior
authorization requirement. The representative wants to increase
utilization. Which of the following strategies is most likely to be
effective and compliant with anti-kickback statutes?
• A) Offer the PBM a volume-based rebate tied to market share
growth, structured as a discount on list price.
• B) Provide free drug samples to the PBM's network physicians to
encourage prescribing.
• C) Sponsor a continuing medical education (CME) program on
diabetes management with an unrestricted educational grant.
• D) Pay a copay assistance program for patients to reduce out-of-
pocket costs, without income verification.
Rationale: Volume-based rebates structured as discounts are generally
permissible under the Anti-Kickback Statute if properly disclosed and not tied
to specific patients. Option B may implicate the federal Anti-Kickback Statute
as free samples can induce prescribing. Option C is permissible but indirect
and may not directly address tier placement. Option D could violate the Anti-
Kickback Statute if it is used to induce the use of a particular drug without
regard to medical necessity .
4. In a sales training session, a manager discusses the importance of
understanding the 'buying center' in a large academic medical center.
Which of the following best describes the composition of the buying
center for a new oncology drug, considering the roles of various
stakeholders?
• A) The pharmacy and therapeutics (P&T) committee alone makes the
formulary decision; prescribers and patients have no formal role.
• B) The buying center includes the P&T committee, key prescribers
(oncologists), pharmacy directors, and financial administrators;
each has distinct influence on adoption.
, • C) Only the hospital CEO and chief financial officer decide on drug
adoption based on budget impact.
• D) The buying center is limited to the medical director and the
pharmacy director; other stakeholders are consulted but not decision-
makers.
Rationale: In large institutions, the buying center is multi-disciplinary,
including P&T committee, prescribers, pharmacy, and finance. Option A is too
narrow; prescribers and patients influence decisions indirectly. Option C is
incorrect because clinical input is crucial. Option D underestimates the role of
the P&T committee and other stakeholders .
5. A sales representative is presenting a new antihypertensive drug
that combines an ACE inhibitor and a thiazide diuretic. The
representative claims that the combination has a synergistic effect on
blood pressure reduction. Which of the following physiological
mechanisms best explains the synergy between these two classes?
• A) ACE inhibitors increase renin release, while thiazides inhibit
aldosterone secretion, leading to additive natriuresis.
• B) Thiazides cause volume depletion, which activates the renin-
angiotensin-aldosterone system; ACE inhibitors block this
compensatory response.
• C) ACE inhibitors directly dilate renal afferent arterioles, while
thiazides constrict efferent arterioles, increasing glomerular filtration
rate.
• D) Both drugs inhibit the same enzyme, leading to a cumulative effect
on angiotensin II levels.
Rationale: Thiazide diuretics reduce blood pressure by depleting sodium and
water, which activates the renin-angiotensin-aldosterone system (RAAS). ACE
inhibitors block this compensatory response, resulting in a synergistic
antihypertensive effect .
